查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1546190

全球免疫測量市場

Radioimmunoassays
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計2030年全球免疫測量市場將達5.871億美元

全球免疫測量市場預估2023年為4.709億美元，預估至2030年將達5.871億美元，2023-2030年分析期間複合年成長率為3.2%。免疫測量試劑和套件是本報告分析的細分市場之一，預計複合年成長率為 3.4%，到分析期結束時將達到 4.587 億美元。分析期間，免疫測量分析儀細分市場的複合年成長率預計為 2.6%。

美國市場預估為1.256億美元，中國預期複合年成長率為2.7%

預計 2023 年美國免疫測量市場規模將達 1.256 億美元。中國作為全球第二大經濟體，預計2023年至2030年將維持2.7%的複合年成長率，到2030年市場規模將達到9,170萬美元。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 3.1% 和 2.6%。在歐洲，德國的複合年成長率預計為 3.3%。

全球免疫測量市場 - 主要趨勢與促進因素總結

免疫測量：徹底改變診斷測試

免疫測量(RIA) 是一種靈敏的實驗室技術，通常用於測量血液或尿液等樣本中特定抗原或荷爾蒙的濃度。此方法使用與目標分子結合的放射性標記抗原或抗體，從而可以對分析物進行準確定量。 RIA 廣泛用於臨床實驗室來檢測和監測各種醫療狀況，包括荷爾蒙失調、感染疾病和癌症。此技術具有高靈敏度和特異性，特別適用於檢測低水平的激素，如胰島素、甲狀腺激素和生殖激素，以及測量腫瘤標記和其他生物標記。 RIA 透過提供對疾病診斷、治療計劃和監測至關重要的準確、可靠的結果，徹底改變了診斷測試。

技術進步如何改善免疫測量？

技術進步顯著提高了免疫測量的性能、安全性和便利性，使其能夠有效地用於廣泛的診斷應用。放射性同位素標記的創新提高了 RIA 試劑的穩定性和靈敏度，從而獲得更準確和一致的結果。自動化 RIA 系統的開發簡化了測試過程，減少了測定準備和分析所需的時間和精力，同時最大限度地降低了人為錯誤的風險。檢測小型化和微孔盤格式的使用的進步提高了 RIA 通量，能夠同時分析多個樣品，並提高了實驗室效率。此外，RIA 與酵素免疫分析法測定 (EIA) 和化學冷光檢測法等其他診斷技術的整合擴大了可檢測和定量的分析物範圍，提供了更全面的診斷資訊。這些技術進步正在推動先進的 RIA 系統在世界各地的臨床實驗室中的採用。

免疫測量在醫學診斷上的主要用途和優點是什麼？

免疫測量廣泛用於診斷應用，具有許多優點，可提高醫學檢測的準確性、可靠性和效率。在內分泌學中，放射免疫分析對於測量糖尿病、甲狀腺疾病、生殖障礙等患者的荷爾蒙水平至關重要，為診斷和治療計劃提供重要資訊。在腫瘤學中，放射免疫分析用於檢測腫瘤標記並監測癌症治療的有效性，從而實現早期療育和個人化治療方法。該技術還可用於傳染病檢查，檢測患者樣本中是否有病毒和細菌抗原，有助於感染疾病的快速診斷和管理。此外，放射免疫分析也用於藥物動力學測量血液中的藥物濃度，以確保劑量正確並監測治療反應。 RIA 的主要優點包括高靈敏度、特異性以及能夠檢測低濃度分析物，使其成為臨床診斷的重要工具。

推動免疫測量市場成長的因素有哪些？

免疫測量市場的成長受到多種因素的推動。癌症、糖尿病和荷爾蒙失調等慢性病的盛行率不斷上升是一個重要的促進因素，因為這些疾病需要精確的診斷測試才能進行有效的管理。放射性同位素標記、自動化和測定小型化的技術進步也透過提高 RIA 系統的性能和效率來推動市場成長。對個人化醫療和標靶治療的需求不斷成長，進一步推動了 RIA 的採用。因為這些技術為個人化治療計劃提供了重要資訊。此外，隨著醫療保健提供者尋求更準確、更可靠的診斷工具，RIAs 在傳染病檢查和藥物動力學等領域的廣泛應用也有助於市場成長。人們對提高診斷準確性和降低醫療成本的興趣日益濃厚，也推動了臨床實驗室採用先進的 RIA 系統。這些因素加上診斷技術的不斷創新，正在推動免疫測量市場的持續成長。

受訪企業範例（44家知名企業）

  • Beckman Coulter, Inc.
  • Berthold Technologies GmbH & Co. KG
  • Cisbio Bioassays
  • DiaSorin SpA
  • Diasource Immunossays SA
  • DRG International, Inc.
  • Euro Diagnostica AB
  • IBL International GmbH
  • Izotop
  • MilliporeSigma
  • MP Biomedicals LLC
  • PerkinElmer, Inc.
  • Stratec Biomedical AG

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP14331

Global Radioimmunoassays Market to Reach US$587.1 Million by 2030

The global market for Radioimmunoassays estimated at US$470.9 Million in the year 2023, is expected to reach US$587.1 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Radioimmunoassay Reagents & Kits, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$458.7 Million by the end of the analysis period. Growth in the Radioimmunoassay Analyzers segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$125.6 Million While China is Forecast to Grow at 2.7% CAGR

The Radioimmunoassays market in the U.S. is estimated at US$125.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$91.7 Million by the year 2030 trailing a CAGR of 2.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Radioimmunoassays Market - Key Trends and Drivers Summarized

Radioimmunoassays: Revolutionizing Diagnostic Testing

Radioimmunoassays (RIAs) are highly sensitive laboratory techniques used to measure the concentration of specific antigens or hormones in a sample, typically blood or urine. The method involves the use of radioactively labeled antigens or antibodies that bind to the target molecule, allowing for precise quantification of the substance of interest. RIAs are widely used in clinical laboratories for the detection and monitoring of various medical conditions, including hormonal disorders, infectious diseases, and cancer. The technique's high sensitivity and specificity make it particularly valuable for detecting low levels of hormones, such as insulin, thyroid hormones, and reproductive hormones, as well as for measuring tumor markers and other biomarkers. RIAs have revolutionized diagnostic testing by providing accurate and reliable results that are critical for disease diagnosis, treatment planning, and monitoring.

How Are Technological Advancements Enhancing Radioimmunoassays?

Technological advancements have significantly improved the performance, safety, and convenience of radioimmunoassays, making them more effective for a wide range of diagnostic applications. Innovations in radioisotope labeling have enhanced the stability and sensitivity of RIA reagents, allowing for more accurate and consistent results. The development of automated RIA systems has streamlined the testing process, reducing the time and labor required for assay preparation and analysis, while also minimizing the risk of human error. Advances in assay miniaturization and the use of microplate formats have increased the throughput of RIAs, enabling the simultaneous analysis of multiple samples and improving laboratory efficiency. Additionally, the integration of RIA with other diagnostic techniques, such as enzyme immunoassays (EIAs) and chemiluminescent assays, has expanded the range of analytes that can be detected and quantified, providing more comprehensive diagnostic information. These technological improvements are driving the adoption of advanced RIA systems in clinical laboratories worldwide.

What Are the Key Applications and Benefits of Radioimmunoassays in Medical Diagnostics?

Radioimmunoassays are used in a wide range of diagnostic applications, offering numerous benefits that enhance the accuracy, reliability, and efficiency of medical testing. In endocrinology, RIAs are essential for measuring hormone levels in patients with conditions such as diabetes, thyroid disorders, and reproductive health issues, providing critical information for diagnosis and treatment planning. In oncology, RIAs are used to detect tumor markers and monitor the effectiveness of cancer therapies, allowing for early intervention and personalized treatment approaches. The technique is also valuable in infectious disease testing, where it can detect the presence of viral or bacterial antigens in patient samples, aiding in the rapid diagnosis and management of infections. Additionally, RIAs are used in pharmacokinetics to measure drug levels in the blood, ensuring appropriate dosing and monitoring therapeutic responses. The primary benefits of RIAs include their high sensitivity, specificity, and ability to detect low concentrations of analytes, making them indispensable tools in clinical diagnostics.

What Factors Are Driving the Growth in the Radioimmunoassays Market?

The growth in the Radioimmunoassays market is driven by several factors. The increasing prevalence of chronic diseases, such as cancer, diabetes, and hormonal disorders, is a significant driver, as these conditions require precise diagnostic testing for effective management. Technological advancements in radioisotope labeling, automation, and assay miniaturization are also propelling market growth by enhancing the performance and efficiency of RIA systems. The rising demand for personalized medicine and targeted therapies is further boosting the adoption of RIAs, as these techniques provide critical information for individualized treatment planning. Additionally, the expanding applications of RIAs in areas such as infectious disease testing and pharmacokinetics are contributing to market growth, as healthcare providers seek more accurate and reliable diagnostic tools. The growing focus on improving diagnostic accuracy and reducing healthcare costs is also supporting the adoption of advanced RIA systems in clinical laboratories. These factors, combined with continuous innovation in diagnostic technology, are driving the sustained growth of the Radioimmunoassays market.

Select Competitors (Total 44 Featured) -

  • Beckman Coulter, Inc.
  • Berthold Technologies GmbH & Co. KG
  • Cisbio Bioassays
  • DiaSorin SpA
  • Diasource Immunossays S.A
  • DRG International, Inc.
  • Euro Diagnostica AB
  • IBL International GmbH
  • Izotop
  • MilliporeSigma
  • MP Biomedicals LLC
  • PerkinElmer, Inc.
  • Stratec Biomedical AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Radioimmunoassays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Sensitive and Specific Diagnostic Tests Propels Market Growth
    • Increasing Use in Clinical and Research Laboratories Expands Addressable Market Opportunity
    • Technological Advancements in Radioimmunoassay Techniques Strengthen Market Position
    • Growing Focus on Early Disease Detection and Monitoring Drives Adoption of Radioimmunoassays
    • Surge in Demand for Hormone and Tumor Marker Testing Generates New Opportunities
    • Development of Automated and High-Throughput Assay Systems Sustains Market Growth
    • Expanding Applications in Endocrinology and Oncology Throws Spotlight on Market Potential
    • Growth in Personalized Medicine and Targeted Therapies Spurs Demand for Radioimmunoassays
    • Rising Adoption of Radioimmunoassays in Academic and Research Institutions Propels Market Expansion
    • Surge in Demand for Radioimmunoassays in Infectious Disease Testing Expands Market Horizons
    • Growing Awareness of the Benefits of Radioimmunoassays in Rare Disease Diagnosis Drives Market Adoption
    • Innovations in Radioactive Labeling and Detection Technologies Generate New Market Opportunities
    • Rising Demand for Radioimmunoassays in Emerging Healthcare Markets Throws Spotlight on Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Radioimmunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Radioimmunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Radioimmunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Radioimmunoassays Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • JAPAN
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • CHINA
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • EUROPE
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Radioimmunoassays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Radioimmunoassays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • FRANCE
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • GERMANY
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030

IV. COMPETITION